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Vasoactive intestinal polypeptide (VIP) secreting tumours are a rare cause of chronic1 or occasionally acute2 secretory 
diarrhoea and more than 90 percent are found in 
the pancreas.3 The tumour incidence is estimated 
to be one in 10 million persons per year.4 They are 
now referred to as VIPomas; 10% of them are neural 
in origin and found mainly in children. The first 
description of an association between a pancreatic 
islet cell tumour and watery diarrhoea was by Priest 
and Alexander in 1957.5 One year later, Verner 
and Morrison described 2 similar patients.6 The 
association between watery diarrhoea and elevated 
VIP levels was reported by Bloom in 1973,7 and 
the clinical syndrome later confirmed when five 
healthy subjects developed profuse diarrhoea 
within 4 hours of receiving an infusion of porcine 
VIP.8 Synonyms include the watery-diarrhoea-
hypokalaemia-achlorhydria (WDHA) syndrome, 
the Verner-Morrison syndrome and pancreatic 
cholera. Functioning neuroendocrine tumours 
(NETs) of the pancreas may secrete a variety of 
different polypeptides causing a variety of different 
syndromes; those that secrete an excess of VIP are 
termed VIPomas, and usually present with chronic 
refractory diarrhoea and are often malignant 
at presentation.1 Differential diagnoses include 
enterotoxin production by vibrio cholera and E.coli, 
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aBStract: We report the case of a 57-year-old male physician who presented with a life threatening secretory 
and refractory diarrhoea of around 20 L/day. This was complicated by severe hypotension, hypokalaemia, 
hypercalcaemia, renal failure requiring dialysis, metabolic acidosis, cardiorespiratory arrest and ventilation for 12 
days.  His diarrhoea responded immediately to the first dose of a therapeutic trial of subcutaneous octreotide 100 
mcg 8 hourly which was started on clinical grounds alone before any investigations were carried out. After one 
day he was extubated and his blood pressure returned to normal. When a functioning neuroendocrine tumour is 
suspected clinically, the use of octreotide can, as in this case, be life saving.
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rectal vilous adenomas and bile salt entropathy.
Case Report
A previously fit Sri Lankan doctor presented to 
his local hospital with a history of well controlled 
diabetes mellitus for 5 years and hypertension for 15 
years; his medications were valsartan, atenolol and 
mixtard insulin. He had noted loose watery motions 
for 2–3 years which he attributed to irritable bowel 
syndrome (IBS). Three months before being referred 
here, his diarrhoea had worsened and he was 
admitted with diabetic ‘ketoacidosis’ and treated 
with intravenous insulin (IV) and fluids. Two days 
later, he developed acute renal failure requiring 
haemodialysis for 3 days. He was treated with 
ciprofloxacin and discharged after two weeks. Three 
weeks later, he was again readmitted with profuse 
watery diarrhoea, confusion, vomitting and acute 
renal failure. Investigations revealed creatinine >300 
µmol/L (normal range [NR] 59–106), potassium 
2.5 mmol/L (NR 3.5–5.0) and calcium of 3.5 
mmol/L (NR 2.2–2.5). During catheter insertion for 
haemodialysis he vomited and aspirated his stomach 
contents resulting in a cardiorespiratory arrest. He 
was intubated and ventilated for 12 days during 
which time he had haemodialysis for three days, 
together with upper and lower gastrointestinal (GI) 
endoscopies which revealed a fluid filled stomach 
and colon with normal appearing mucosa. On his 
final admission to the referring hospital, he was 
started on ciprofloxacin, metronidazole, octreotide 
50 mcg twice daily as a neuroendocrine tumour 
was considered as one of the differential diagnoses. 
After several days, however, the diarrhoea still 
persisted and metronidazole was added to treat 
possible antibiotic-associated diarrhoea.  Extubation 
failed on at least two occasions; he was then 
transferred to Sultan Qaboos University Hospital 
by aeroplane on a ventilator, intravenous fluid and 
ionatropes. During the flight his blood pressure fell 
to 30 systolic. On arrival here, he was gravely ill with 
a blood pressure (BP) of 45/30 on dopamine and IV 
fluids. The serum creatinine was now 180 µmol/L, 
potassium 2.8 mmol/L, HCO3 10 mmol/L (NR 22–
29), Hb 19 gm/dl (n 11.5–15.0). The estimated stool 
volume before receiving octreotide was as much at 
20 liters/day as within 12 hours he had passed 12 
liters by rectal tube.
An endocrine consultation was asked for 12 
hours after his admission and based on his history, 
the presence of secretory odourless diarrhoea, 
hypokalaemia and metabolic acidosis, a clinical 
diagnosis of VIPoma was made. The patient was 
then immediately started on a therapeutic trial of 
octreotide, 100 mcg 8 hourly, after taking blood 
samples to test for for VIP, chromogranin A and 
other hormone levels. His response was dramatic 
and similar to a patient treated with long acting 
octreotide in 1985 who also had an immediate 
cessation of diarrhoea.9 One day later, the diarrhoea 
had improved substantially; he was extubated, the 
dopamine stopped and his BP returned to normal. 
By day four, his electrolyte profile was normal 
without any additional therapy [Table 1].
An abdominal ultrasound revealed an 8 cm mass 
in the left upper quadrant. Computed tomography 
(CT) and magnetic resonance imaging (MRI) scans 
Table 1: Stool volume: response to octreotide 100 mcg 
8 hourly.
Figure 1: MRI scan showing pancreatic tail mass 8.2 x 
7.5 cm with necrosis. 
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[Figure 1] of the abdomen revealed an 8.2 x 7.5 cm 
well encapsulated and necrotic pancreatic tail mass 
with no evidence of metastases. After three weeks 
on octreotide, the patient had gained 7 kg and felt 
quite normal.
On day 21, he underwent a distal pancreatectomy 
and splenectomy [Figure 2]. No liver, peritoneal 
or lymph node metastases were seen. The patient 
had an uneventful postoperative course and the 
diarrhoea has not since recurred. The octreotide 
was stopped four days after surgery.
Histological examination revealed a NET with 
partial capsular invasion [Figure 3] strongly positive 
for chromogrannin A [Figure 4] and VIP. A minority 
of cells were positive for glucagon and pancreatic 
polypeptide (PP). The margins of the pancreas were 
free of tumour and the spleen was normal. Two 
weeks post surgery, the repeated VIP test revealed 
a level of 46 and chromogranin A 37, both normal 
(Table 2). An octreoscan performed 14 weeks after 
surgery showed no evidence of recurrence. 
Discussion
This patient’s symptoms improved immediately 
with the introduction of octreotide in a dose of 
100 mcg thrice daily having previously failed 
to respond to a much smaller dose. VIP is a 28 
aminoacid polypeptide which is widely distributed 
throughout the body and normally functions as a 
neurotransmitter. In the gut, VIP regulates the 
blood flow, smooth muscle activity, pancreatic 
and intestinal secretions and inhibits gastric acid 
production. It also stimulates intestinal water, 
sodium and chloride secretion, inhibits resorption 
and increases colonic potassium secretion.10
VIPomas are rare NETs with only 241 cases 
reported worldwide until 1998.11 Our patient’s 
presentation was typical with copious watery 
odourless diarrhoea, hypokalaemia and metabolic 
acidosis.12 The secretory nature of the diarrhoea 
was confirmed by its failure to respond to fasting. 
Hypokalaemia results from losses in the stool and 
the acidosis from a combination of dehydration, 
hypotension and renal failure which was profound 
in our patient due to his massive stool volumes 
estimated to be up to 20 litres/day. This is much 
more than the usually reported volumes of 6–8 
litres daily,12.13 Hyperglycaemia occurs in one third 
of patients and results from increased hepatic 
glucogenolysis caused by the elevated VIP levels.4 
However, this was not the mechanism in our 
Figure 2: Specimen: Pancreatic tail with tumour and 
spleen. 
Figure 3: Partial capsular invasion by the tumour.
Figure 4: Immunohistochemistry stain positive for 
vasoactive intestinal polypeptide (shown as dark 
brown).
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patient as his insulin requirement did not change 
following treatment with octreotide, resection of 
the tumour, and normalisation of the VIP levels. The 
patient’s hypercalcaemia resolved during treatment 
with octreotide and intravenous fluids excluding 
associated hyperparathyroidism; it was related 
either to dehydration induced hyperalbuminaemia 
or to increased bone resorption caused by excessive 
VIP or other peptides produced by the tumour.13
Octreotide controls symptoms and normalises 
VIP levels in nearly 90% of patients often with 
extensive metastatic disease.4 Because our patient 
was so ill, octreotide was given as an immediate 
therapeutic trial before tumour localisation studies 
were carried out. The results were remarkable and 
gratifying; the diarrhea improving substantially 
after his first 100 mcg injection [Tables 1 and 2]. 
Octreotide was continued until 4 days after surgery 
at which time he had gained 7 kg. More than 70% 
of VIPoma patients present with metastatic 
disease.13 Fortunately, this was not the case here, but 
his tumour was large and histologically reported as 
a tumour of uncertain behaviour. He will therefore 
be followed up with serial VIP measurements and, 
if indicated, further octreotide scanning.
Conclusion
To conclude, this was a case of unexplained massive 
watery diarrhoea which responded immediately to 
octreotide treatment. Clinicians facing similar cases 
should prescribe a therapeutic trial of octreotide 
without waiting for the results of investigations as 
it might be life saving.
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Table 2: Serum peptide and electrolyte levels before (day 0) and upon discharge.  CG-A: chromogranin A





900 240 2.5 180 10 3.5
Post surgery 
Day 31
46 37 4.1 70 26 2.2
Normal range <65 <100 >3.5 <104 >18 <2.6
